Tags

Type your tag names separated by a space and hit enter

Maternal Inositol Status and Neural Tube Defects: A Role for the Human Yolk Sac in Embryonic Inositol Delivery?
Adv Nutr. 2021 02 01; 12(1):212-222.AN

Abstract

Supplementation with myo-inositol during the periconceptional period of pregnancy may ameliorate the recurrence risk of having a fetus affected by a neural tube defect (NTD; e.g., spina bifida). This could be of particular importance in providing a means for preventing NTDs that are unresponsive to folic acid. This review highlights the characteristics of inositol and describes the role of myo-inositol in the prevention of NTDs in rodent studies and the evidence for its efficacy in reducing NTD risk in human pregnancy. The possible reduction in NTD risk by maternal myo-inositol implies functional and developmentally important maternal-embryonic inositol interrelationships and also suggests that embryonic uptake of myo-inositol is crucial for embryonic development. The establishment of active myo-inositol cellular uptake mechanisms in the embryonic stages of human pregnancy, when the neural tube is closing, is likely to be an important determinant of normal development. We draw attention to the generation of materno-fetal inositol concentration gradients and relationships, and outline a transport pathway by which myo-inositol may be delivered to the early developing human embryo. These considerations provide novel insights into the mechanisms that may underpin inositol's ability to confer embryonic developmental benefit.

Links

PMC Free PDF

Authors+Show Affiliations

D'Souza SW
Maternal and Fetal Health Research Centre, St. Mary's Hospital, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.
Copp AJ
Newlife Birth Defects Research Centre, Developmental Biology and Cancer Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Greene NDE
Newlife Birth Defects Research Centre, Developmental Biology and Cancer Department, UCL Great Ormond Street Institute of Child Health, London, United Kingdom.
Glazier JD
Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom.

MeSH

FemaleFolic AcidHumansInositolNeural Tube DefectsPregnancySpinal DysraphismYolk Sac

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

32892218

Citation

D'Souza, Stephen W., et al. "Maternal Inositol Status and Neural Tube Defects: a Role for the Human Yolk Sac in Embryonic Inositol Delivery?" Advances in Nutrition (Bethesda, Md.), vol. 12, no. 1, 2021, pp. 212-222.
D'Souza SW, Copp AJ, Greene NDE, et al. Maternal Inositol Status and Neural Tube Defects: A Role for the Human Yolk Sac in Embryonic Inositol Delivery? Adv Nutr. 2021;12(1):212-222.
D'Souza, S. W., Copp, A. J., Greene, N. D. E., & Glazier, J. D. (2021). Maternal Inositol Status and Neural Tube Defects: A Role for the Human Yolk Sac in Embryonic Inositol Delivery? Advances in Nutrition (Bethesda, Md.), 12(1), 212-222. https://doi.org/10.1093/advances/nmaa100
D'Souza SW, et al. Maternal Inositol Status and Neural Tube Defects: a Role for the Human Yolk Sac in Embryonic Inositol Delivery. Adv Nutr. 2021 02 1;12(1):212-222. PubMed PMID: 32892218.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Maternal Inositol Status and Neural Tube Defects: A Role for the Human Yolk Sac in Embryonic Inositol Delivery? AU - D'Souza,Stephen W, AU - Copp,Andrew J, AU - Greene,Nicholas D E, AU - Glazier,Jocelyn D, PY - 2020/02/25/received PY - 2020/06/10/revised PY - 2020/07/28/accepted PY - 2020/9/7/pubmed PY - 2021/3/3/medline PY - 2020/9/6/entrez KW - myo-inositol KW - fetus KW - folate KW - placenta KW - polyol KW - pregnancy SP - 212 EP - 222 JF - Advances in nutrition (Bethesda, Md.) JO - Adv Nutr VL - 12 IS - 1 N2 - Supplementation with myo-inositol during the periconceptional period of pregnancy may ameliorate the recurrence risk of having a fetus affected by a neural tube defect (NTD; e.g., spina bifida). This could be of particular importance in providing a means for preventing NTDs that are unresponsive to folic acid. This review highlights the characteristics of inositol and describes the role of myo-inositol in the prevention of NTDs in rodent studies and the evidence for its efficacy in reducing NTD risk in human pregnancy. The possible reduction in NTD risk by maternal myo-inositol implies functional and developmentally important maternal-embryonic inositol interrelationships and also suggests that embryonic uptake of myo-inositol is crucial for embryonic development. The establishment of active myo-inositol cellular uptake mechanisms in the embryonic stages of human pregnancy, when the neural tube is closing, is likely to be an important determinant of normal development. We draw attention to the generation of materno-fetal inositol concentration gradients and relationships, and outline a transport pathway by which myo-inositol may be delivered to the early developing human embryo. These considerations provide novel insights into the mechanisms that may underpin inositol's ability to confer embryonic developmental benefit. SN - 2156-5376 UR - https://www.unboundmedicine.com/medline/citation/32892218/Maternal_Inositol_Status_and_Neural_Tube_Defects:_A_Role_for_the_Human_Yolk_Sac_in_Embryonic_Inositol_Delivery DB - PRIME DP - Unbound Medicine ER -